229 related articles for article (PubMed ID: 27324680)
1. CKD-Mineral Bone Disorder in Stage 4 and 5 CKD: What We Know Today?
Melamed ML; Buttar RS; Coco M
Adv Chronic Kidney Dis; 2016 Jul; 23(4):262-9. PubMed ID: 27324680
[TBL] [Abstract][Full Text] [Related]
2. Caring for chronic kidney disease patients: focus on mineral and bone disorders.
Nguyen TV; Filson J
Consult Pharm; 2009 Feb; 24(2):146-52. PubMed ID: 19275456
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.
Joy MS; Karagiannis PC; Peyerl FW
J Manag Care Pharm; 2007 Jun; 13(5):397-411. PubMed ID: 17605511
[TBL] [Abstract][Full Text] [Related]
4. Treatment of hyperphosphatemia: the dangers of aiming for normal PTH levels.
Haffner D; Leifheit-Nestler M
Pediatr Nephrol; 2020 Mar; 35(3):485-491. PubMed ID: 31823044
[TBL] [Abstract][Full Text] [Related]
5. Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study.
Gallieni M; De Luca N; Santoro D; Meneghel G; Formica M; Grandaliano G; Pizzarelli F; Cossu M; Segoloni G; Quintaliani G; Di Giulio S; Pisani A; Malaguti M; Marseglia C; Oldrizzi L; Pacilio M; Conte G; Dal Canton A; Minutolo R
J Nephrol; 2016 Feb; 29(1):71-8. PubMed ID: 25986389
[TBL] [Abstract][Full Text] [Related]
6. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
Molony DA; Stephens BW
Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
[TBL] [Abstract][Full Text] [Related]
7. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
[TBL] [Abstract][Full Text] [Related]
8. Treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Komaba H; Tanaka M; Fukagawa M
Intern Med; 2008; 47(11):989-94. PubMed ID: 18520108
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor-23 helps explain the biphasic cardiovascular effects of vitamin D in chronic kidney disease.
Hu P; Xuan Q; Hu B; Lu L; Wang J; Qin YH
Int J Biol Sci; 2012; 8(5):663-71. PubMed ID: 22606047
[TBL] [Abstract][Full Text] [Related]
10. Impact of Cinacalcet and Etelcalcetide on Bone Mineral and Cardiovascular Disease in Dialysis Patients.
Bernardor J; De Mul A; Bacchetta J; Schmitt CP
Curr Osteoporos Rep; 2023 Apr; 21(2):193-204. PubMed ID: 36848027
[TBL] [Abstract][Full Text] [Related]
11. Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals.
Kalantar-Zadeh K; Shah A; Duong U; Hechter RC; Dukkipati R; Kovesdy CP
Kidney Int Suppl; 2010 Aug; (117):S10-21. PubMed ID: 20671739
[TBL] [Abstract][Full Text] [Related]
12. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
[TBL] [Abstract][Full Text] [Related]
13. Treatment of hyperphosphatemia: the dangers of high PTH levels.
Bacchetta J
Pediatr Nephrol; 2020 Mar; 35(3):493-500. PubMed ID: 31696357
[TBL] [Abstract][Full Text] [Related]
14. The impact of cinacalcet in the mineral metabolism markers of patients on dialysis with severe secondary hyperparathyroidism.
Bucharles SGE; Barreto FC; Riella MC
J Bras Nefrol; 2019 Jul; 41(3):336-344. PubMed ID: 31419274
[TBL] [Abstract][Full Text] [Related]
15. The rationale for intermittent administration of PTH in the management of mineral and bone disorder of chronic kidney disease.
Pazianas M; Miller PD
J Nephrol; 2024 Mar; 37(2):337-342. PubMed ID: 37171706
[TBL] [Abstract][Full Text] [Related]
16. [Therapeutic indications obtained from short- and medium-term biohumoral changes after parathyroidectomy].
Sforzini S; Viganò MR; Rosa M; Redaelli B
Minerva Med; 1985 Mar; 76(9-10):393-6. PubMed ID: 3982696
[No Abstract] [Full Text] [Related]
17. [New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of Nephrologists form Lombardy].
Bellasi A; Cozzolino M; Malberti F; Cancarini G; Esposito C; Genderini A; Guastoni CM; Ondei P; Pontoriero G; Teatini U; Vezzoli G; Messa P; Locatelli F
G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786181
[TBL] [Abstract][Full Text] [Related]
18. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters.
Ketteler M; Block GA; Evenepoel P; Fukagawa M; Herzog CA; McCann L; Moe SM; Shroff R; Tonelli MA; Toussaint ND; Vervloet MG; Leonard MB
Kidney Int; 2017 Jul; 92(1):26-36. PubMed ID: 28646995
[TBL] [Abstract][Full Text] [Related]
19. [Physiopathology of renal osteodystrophy. I. Patients with kidney failure without dialysis].
Fournier A; Bordier P; Weil B; Safar M; Idatte JM
Presse Med (1893); 1971 Oct; 79(45):2017-21. PubMed ID: 5119047
[No Abstract] [Full Text] [Related]
20. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
